170 related articles for article (PubMed ID: 30046226)
1. Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer.
Liu X; Ran R; Shao B; Rugo HS; Yang Y; Hu Z; Wei Z; Wan F; Kong W; Song G; Jiang H; Liang X; Zhang R; Yan Y; Xu G; Li H
Chin J Cancer Res; 2018 Jun; 30(3):315-326. PubMed ID: 30046226
[TBL] [Abstract][Full Text] [Related]
2. Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients.
Liu XR; Shao B; Peng JX; Li HP; Yang YL; Kong WY; Song GH; Jiang HF; Liang X; Yan Y
Breast; 2017 Apr; 32():119-125. PubMed ID: 28157583
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
5. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
6. First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial.
Liu MC; Janni W; Georgoulias V; Yardley DA; Harbeck N; Wei X; McGovern D; Beck R
Cancer Manag Res; 2019; 11():10427-10433. PubMed ID: 31849532
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer.
Guan X; Li C; Li Y; Wang J; Yi Z; Liu B; Chen H; Xu J; Qian H; Xu B; Ma F
Front Oncol; 2021; 11():602222. PubMed ID: 34150608
[TBL] [Abstract][Full Text] [Related]
8. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
9. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN
Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cell analysis in metastatic triple-negative breast cancers.
Magbanua MJ; Carey LA; DeLuca A; Hwang J; Scott JH; Rimawi MF; Mayer EL; Marcom PK; Liu MC; Esteva FJ; Park JW; Rugo HS;
Clin Cancer Res; 2015 Mar; 21(5):1098-105. PubMed ID: 25524311
[TBL] [Abstract][Full Text] [Related]
11. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients.
Wallwiener M; Riethdorf S; Hartkopf AD; Modugno C; Nees J; Madhavan D; Sprick MR; Schott S; Domschke C; Baccelli I; Schönfisch B; Burwinkel B; Marmé F; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2014 Jul; 14():512. PubMed ID: 25015676
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
13. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.
Wang C; Mu Z; Chervoneva I; Austin L; Ye Z; Rossi G; Palazzo JP; Sun C; Abu-Khalaf M; Myers RE; Zhu Z; Ba Y; Li B; Hou L; Cristofanilli M; Yang H
Breast Cancer Res Treat; 2017 Jan; 161(1):83-94. PubMed ID: 27771841
[TBL] [Abstract][Full Text] [Related]
14. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
Zhou J; Dong F; Cui F; Xu R; Tang X
Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
[TBL] [Abstract][Full Text] [Related]
15. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
16. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
Li Y; Peng Z; Zhang X; Gong J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
[TBL] [Abstract][Full Text] [Related]
17. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cells (CTCs) and cytokeratin 19 (CK19) mRNA as prognostic factors in heavily pretreated patients with metastatic breast cancer.
Morales S; Velasco A; Gasol A; Córdoba F; Vidal J; Serrate A; Valls J; Samame JC; Gisbert R; Moral D; Llombart-Cussac A; Salud A; Matias-Guiu X
Cancer Treat Res Commun; 2018; 16():13-17. PubMed ID: 31298997
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T;
Breast Cancer Res; 2012 Aug; 14(4):R118. PubMed ID: 22894854
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial.
Basso U; Facchinetti A; Rossi E; Maruzzo M; Conteduca V; Aieta M; Massari F; Fraccon AP; Mucciarini C; Sava T; Santoni M; Pegoraro C; Durante E; Nicodemo M; Perin A; Bearz A; Gatti C; Fiduccia P; Diminutto A; Barile C; De Giorgi U; Zamarchi R; Zagonel V
Oncologist; 2021 Sep; 26(9):740-750. PubMed ID: 34077597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
